This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Papetti, M. Articles by Skoultchi, A. I. Search for Related Content PubMed PubMed Citation Articles by Papetti, M. Articles by Skoultchi, A. I.

---

Cancer Genes and Genomics

Reprogramming Leukemia Cells to Terminal Differentiation and Growth Arrest by RNA Interference of PU.1

Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York

Requests for reprints: Arthur I. Skoultchi, Department of Cell Biology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Chanin Building, Room 402, Bronx, NY 10461. Phone: 718-430-2168. E-mail: skoultch{at}aecom.yu.edu

Malignant transformation often leads to both loss of normal proliferation control and inhibition of cell differentiation. Some tumor cells can be stimulated to reenter their differentiation program and to undergo terminal growth arrest. The in vitro differentiation of mouse erythroleukemia (MEL) cells is an important example of tumor cell reprogramming. MEL cells are malignant erythroblasts that are blocked from differentiating into mature RBC due to dysregulated expression of the transcription factor PU.1, which binds to and represses GATA-1, the major transcriptional regulator of erythropoiesis. We used RNA interference to ask whether inhibiting PU.1 synthesis was sufficient to cause MEL cells to lose their malignant properties. We report here that transfection of MEL cells with a PU.1-specific short interfering RNA oligonucleotide causes the cells to resume erythroid differentiation, accumulate hemoglobin, and undergo terminal growth arrest. RNA interference directed at specific, aberrantly expressed transcription factors may hold promise for the development of potent antitumor therapies in other hematologic malignancies. (Mol Cancer Res 2007;5(10):1053–62)